<?xml version="1.0" encoding="UTF-8"?>
<p id="Par54">Nevertheless, in order to gain widespread acceptance and reimbursement from health care systems, pivotal studies as well as large RCT better addressing the cell mode of action (MoA) are still awaited [
 <xref ref-type="bibr" rid="CR14">14</xref>]. Moreover, the priority issue about safety and efficacy in the subset of RA patients with LV dysfunction remains to be confirmed, for which less information is available in the literature.
</p>
